Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies

dc.creatorTESAN, FIORELLA
dc.creatorCERQUEIRA-COUTINHO, CRISTAL
dc.creatorSALGUEIRO, JIMENA
dc.creatorALBERNAZ, MARTA de S.
dc.creatorPINTO, SUYENNE R.
dc.creatorREIS, SARA R.R. dos
dc.creatorBERNARDES, EMERSON S.
dc.creatorCHIAPETTA, DIEGO
dc.creatorZUBILLAGA, MARCELA
dc.creatorSANTOS-OLIVEIRA, RALPH
dc.date2016
dc.date2017-10-06T13:53:28Z
dc.date2017-10-06T13:53:28Z
dc.date.accessioned2023-09-28T14:03:52Z
dc.date.available2023-09-28T14:03:52Z
dc.identifier1773-2247
dc.identifierhttp://repositorio.ipen.br/handle/123456789/27856
dc.identifier36
dc.identifier10.1016/j.jddst.2016.09.011
dc.identifier16.148
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8998113
dc.descriptionBevacizumab is an FDA approved monoclonal antibody (anti VEGF) indicated in many cancers, mostly metastatic ones. D-alpha-tocopheryl polyethylene glycol succinate (TPGS) is the water-soluble form of vitamin E which usually forms micelles. This work aims to report preliminary results of the biodistribution of a TPGS based nano-micelle delivery system for bevacizumab in a gastric cancer xenograft model. Evaluation of the biodistribution of micelles/bevacizumab-99mTc was performed in Balb/c nude mice carrying MKN45 cell line xenograft. The nano-radiopharmaceutical (3.7 MBq/0.2 mL) was administered intraocularly and biodistribution was assesed 1 h post administration. The activity in each organ and blood was determined by a gamma counter. Mean size was 10 +/- 1 nm for pure TPGS and 11 +/- 1 nm for bevacizumab-TPGS respectively. Biodistribution showed that the highest uptake was found in both lungs and liver. Kidneys had also an important uptake. The tumor accumulated moderate to low radiolabeled nanomicelles, nevertheless tumor/blood ratio was very high. These preliminary results may help as a start point to continue evaluating the potential of radiolabeled bevacizumab-TPGS based nanomicelles to be used as a theranostic agent.
dc.format95-98
dc.relationJournal of Drug Delivery Science and Technology
dc.rightsopenAccess
dc.subjectpolyethylene glycols
dc.subjectglycols
dc.subjectpolyethylenes
dc.subjectdrugs
dc.subjectchemotherapy
dc.subjectmolecular biology
dc.subjectcarcinomas
dc.titleCharacterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies
dc.typeArtigo de peri??dico
dc.coverageI


Este ítem pertenece a la siguiente institución